Verve TherapeuticsVERV
13F holders, Q4 2025 (December 31)1holders −5
0new positions
5sold out
$14.33avg. 13F price*
At the end of Q4 2025, 1 institutions reported holding Verve Therapeutics Inc. (VERV) in their 13F filings, down 5 from Q3 2025. 0 opened new positions and 5 sold out. The largest holder was DekaBank Deutsche Girozentrale ($344K).
- Company
- Verve Therapeutics Inc.
- CUSIP
- 92539P101
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 5 | $902K |
All 13F filers, Q3 2025 → Q4 2025: 205,257 shares sold, net −205,257 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| DekaBank Deutsche Girozentrale | 0.00% | No change | 24,000 | $344K |
"% of holder's portfolio" is VERV's weight in each manager's 13F, not the share of Verve Therapeutics Inc. the manager owns.